Guhan Pharmaceutical Group Co

Guhan Pharmaceutical Group Co EBIT per Share

The EBIT per Share of Guhan Pharmaceutical Group Co (000590.SZ) as of Oct 30, 2026 is -0.20 CNY. In the previous year, EBIT per Share was -0.70 CNY — a change of -72.27% (higher).

EBIT per Share

-0.20CNY

YoY

-72.27%

Last updated:

EBIT per Share of Guhan Pharmaceutical Group Co is 2025 -0.20 CNY. EBIT per Share of Guhan Pharmaceutical Group Co was 2024 -0.70 CNY. It decreases by -72.27% higher compared to the previous year.

The Guhan Pharmaceutical Group Co EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2018
-0.15 CNY
Jan 1, 2019
0.22 CNY
Jan 1, 2020
0.12 CNY
Jan 1, 2021
0.18 CNY
Jan 1, 2022
0.09 CNY
Jan 1, 2023
0.09 CNY
Jan 1, 2024
-0.70 CNY
Jan 1, 2025
-0.20 CNY
The Guhan Pharmaceutical Group Co EBIT per Share history
YEAREBIT per ShareYoY
-0.20CNY-72.27%
-0.70CNY-862.11%
0.09CNY-2.14%
0.09CNY-46.60%
0.18CNY+52.51%
0.12CNY-46.58%
0.22CNY-247.53%
-0.15CNY-101.53%
9.64CNY-103.38%
-285.17CNY-218,238.49%
0.13CNY-142.57%
-0.31CNY-46.92%
-0.58CNY-373.91%
0.21CNY-43.99%
0.38CNY+36.45%
0.28CNY-185.50%
-0.32CNY-364.26%
0.12CNY+9.53%
0.11CNY+819.71%
0.01CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Guhan Pharmaceutical Group Co Stock analysis

What does Guhan Pharmaceutical Group Co do? Tus-Pharmaceutical Group Co., Ltd. generates revenue through the research and development, production, and sales of Chinese patent medicine and western medicine preparations. The company offers Chinese healthcare products, cold treatment medicines, and anti hyperlipemia medicines, alongside western medicine products such as clindamycin phosphate for injection, lomefloxacin hydrochloride for injection, and levofloxacin lactate for injection. Domestic markets are the primary sales channel for all products. The firm's revenue streams are derived from the sale of these pharmaceutical products to domestic customers. The company focuses on Chinese patent medicine, including healthcare products, cold treatment remedies, and anti hyperlipemia treatments. Western medicine preparations like clindamycin phosphate for injection, lomefloxacin hydrochloride for injection, and levofloxacin lactate for injection form a significant part of its product portfolio. These products are distributed exclusively within China, targeting domestic consumers and healthcare providers. Tus-Pharmaceutical Group Co., Ltd. serves domestic markets with its range of Chinese and western medicines. The company's product lines include Chinese healthcare products, cold treatment medicines, anti hyperlipemia medicines, and specific western medicine injections. Sales are conducted within China, with no mention of international distribution. The firm's revenue is generated through the direct sale of these pharmaceutical products to domestic buyers. Guhan Pharmaceutical Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Guhan Pharmaceutical Group Co stock

EBIT per Share of Guhan Pharmaceutical Group Co is -0.20 CNY in 2025.

EBIT per Share of Guhan Pharmaceutical Group Co changed from -0.70 CNY to -0.20 CNY, representing a -72.27% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Guhan Pharmaceutical Group Co since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Guhan Pharmaceutical Group Co

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Guhan Pharmaceutical Group Co